Warshauer Emily, Warshauer Bruce L
Center for Pediatric, Adolescent, and Adult Dermatology, Point Pleasant, NJ, USA.
J Drugs Dermatol. 2008 May;7(5):447-51.
The short-term and long-term outcomes of 108 patients with 122 nodular basal cell carcinomas (BCCs), morpheaform BCCs, or low-risk squamous cell carcinomas (SCCs) treated with imiquimod 5% cream at a community-based dermatology practice were retrospectively reviewed. The overall initial tumor clinical cure rate was 93.4% (114/122), with an initial clinical cure rate of 90% (72/80) for BCCs combined, and 100% (42/42) for SCCs combined. During a median follow-up time of 18 months, there was only 1 recurrence in the 114 tumors considered initially clinically cured. Imiquimod may be an appropriate initial treatment for these tumors in patients with good posttreatment follow-up.
对一家社区皮肤科诊所中108例患有122个结节性基底细胞癌（BCC）、硬斑病样BCC或低风险鳞状细胞癌（SCC）的患者使用5%咪喹莫特乳膏治疗的短期和长期结果进行了回顾性研究。总体初始肿瘤临床治愈率为93.4%（114/122），其中BCC联合的初始临床治愈率为90%（72/80），SCC联合的初始临床治愈率为100%（42/42）。在中位随访时间18个月期间，在最初被认为临床治愈的114个肿瘤中仅出现1例复发。对于治疗后随访良好的患者，咪喹莫特可能是这些肿瘤的一种合适的初始治疗方法。
